Literature DB >> 9431967

Long-term predictive value of a single cytomegalovirus (CMV) DNA PCR assay for CMV disease in human immunodeficiency virus-infected patients.

S Walmsley1, T Mazzulli, M Krajden.   

Abstract

Universal prophylaxis with oral ganciclovir is not cost-effective for the prevention of cytomegalovirus (CMV) disease in human immunodeficiency virus infection. For a preemptive strategy to be considered, patients at highest risk for CMV disease need to be easily and accurately identified. In this study, the sensitivity, specificity, positive predictive value, and negative predictive value of a single CMV DNA PCR assay for the subsequent development of CMV disease were 0.75, 0.89, 0.75, and 0.89, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9431967      PMCID: PMC124854     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival.

Authors:  E F Bowen; P Wilson; A Cope; C Sabin; P Griffiths; C Davey; M Johnson; V Emery
Journal:  AIDS       Date:  1996-11       Impact factor: 4.177

2.  A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood.

Authors:  J E Grundy; A Ehrnst; H Einsele; V C Emery; H Hebart; H G Prentice; P Ljungman
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

3.  Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.

Authors:  M A Jacobson; M Zegans; P R Pavan; J J O'Donnell; F Sattler; N Rao; S Owens; R Pollard
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

4.  Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection System.

Authors:  G Boivin; J Handfield; G Murray; E Toma; R Lalonde; J G Lazar; M G Bergeron
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

5.  Evaluation of the Digene Hybrid Capture System for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus-infected patients.

Authors:  T Mazzulli; S Wood; R Chua; S Walmsley
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

6.  Interest of quantitative pp65 cytomegalovirus antigenemia assay for human immunodeficiency virus-positive patients.

Authors:  S Ranger-Rogez; J P Couty; T Nicot; F Denis; J P Rogez; A Riche; P Weinbreck
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

7.  High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up.

Authors:  B Bek; M Boeckh; J Lepenies; B Bieniek; K Arasteh; W Heise; K M Deppermann; G Bornhöft; M Stöffler-Meilicke; I Schuller; G Höffken
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

8.  Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test.

Authors:  K K Dodt; P H Jacobsen; B Hofmann; C Meyer; H J Kolmos; P Skinhøj; B Norrild; L Mathiesen
Journal:  AIDS       Date:  1997-03       Impact factor: 4.177

9.  Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease.

Authors:  P E Wetherill; M L Landry; P Alcabes; G Friedland
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-05-01

Review 10.  Lessons learned from HIV pathogenesis and therapy: implications for better management of cytomegalovirus disease.

Authors:  W D Hardy
Journal:  AIDS       Date:  1996-11       Impact factor: 4.177

View more
  1 in total

1.  Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients.

Authors:  I Pellegrin; I Garrigue; C Binquet; G Chene; D Neau; P Bonot; F Bonnet; H Fleury; J L Pellegrin
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.